Chloroquine makes comeback to combat malaria

October 03, 2012

Malaria-drug monitoring over the past 30 years has shown that malaria parasites develop resistance to medicine, and the first signs of resistance to the newest drugs have just been observed. At the same time, resistance monitoring at the University of Copenhagen shows that the previously efficacious drug chloroquine is once again beginning to work against malaria. In time that will ensure cheaper treatment for the world's poor.

Scientists and healthcare personnel the world over fear that the malaria parasite will develop resistance to the current frontline treatment against malaria, Artemisinin-based Combination Therapies (ACTs). Therefore, it is especially good news that resistance monitoring at the University of Copenhagen shows that in several African countries, malaria parasites are succumbing to the formerly used drug chloroquine. The results have just been published in the American Journal of Tropical Medicine and Hygiene.

"70% of the malaria parasites we found in Senegal are reacting once again to chloroquine. This is a trend we have also seen in Tanzania and Mozambique, and which other researchers have shown in Malawi. Our choice of drugs against malaria is limited and related, so when the malaria parasite once again reacts to a substance, it influences several treatment methods," explains Michael Alifrangis, associate professor at the Center for Medical Parasitology at the University of Copenhagen. He and Magatte Ndiaye, PhD student at Université Cheikh Anta Diop in Senegal, are keeping an eye on the malaria parasite's sensitivity to drugs by analyzing the parasites' DNA.

Cheaper treatment for the poor in Africa

If healthcare personnel in developing countries can begin using chloroquine again, it will open up some promising perspectives. It will be possible to protect the currently used medicine and delay the reappearance of resistance, and it will also give a large group of patients access to cheaper treatment.

"Chloroquine costs only 25 US cents for a four-day cure, while the current and corresponding ACTs cost two dollars. Chloroquine was a fantastic malaria drug that lasted for 50 years. However, it was misused for malaria prevention and ordinary fever, and even mixed with cooking salt, so it can come as no surprise that the malaria parasite became resistant to the active ingredient," explains Professor Ib Bygbjerg, M.D. He also points out that reuse will require correct drug use and the training of healthcare personnel to make more accurate diagnoses.

Correct use of drugs paralyzes the development of resistance

According to Professor Ib Bygbjerg, three factors determine the extent to which a malaria drug will work: 1) the size of the dose, 2) how sensitive the parasite is to the drug, and 3) the extent to which the patient has developed a natural immunity to malaria.

"In the near future, chloroquine and other malaria drugs not currently on the market will presumably be able to be used again, if we use them correctly. This means that the drug must be given in combination with other medicine and only to patients who have already developed a certain immunity to malaria and are therefore not at high risk. At the same time, we must reserve ACTs for the most exposed non-immune groups such as children. Chloroquine is one of the few drugs that can be given to pregnant women at the beginning of their pregnancy," points out Ib Bygbjerg, adding that the patient can be treated with a high dose for a short period, another benefit.

In order to maintain the positive development with chloroquine, it is therefore also important that - with the exception of pregnant women - travellers to malaria areas refrain from taking the drug. Otherwise the parasites will quickly develop resistance once again.
-end-
ContactAssociate Professor Michael Alifrangis
E-mail: micali@sund.ku.dk
Tel. + 45 2345 1804

Professor Ib Bygbjerg, M.D.
E-mail: iby@sund.ku.dk
Tel. + 45 41 58 94 97

Lasse Jensen, Communications Officer
E-mail: lassej@sund.ku.dk
Tel.: +45 21 84 74 91

University of Copenhagen

Related Malaria Articles from Brightsurf:

Clocking in with malaria parasites
Discovery of a malaria parasite's internal clock could lead to new treatment strategies.

Breakthrough in malaria research
An international scientific consortium led by the cell biologists Volker Heussler from the University of Bern and Oliver Billker from the UmeƄ University in Sweden has for the first time systematically investigated the genome of the malaria parasite Plasmodium throughout its life cycle in a large-scale experiment.

Scientists close in on malaria vaccine
Scientists have taken another big step forward towards developing a vaccine that's effective against the most severe forms of malaria.

New tool in fight against malaria
Modifying a class of molecules originally developed to treat the skin disease psoriasis could lead to a new malaria drug that is effective against malaria parasites resistant to currently available drugs.

Malaria expert warns of need for malaria drug to treat severe cases in US
The US each year sees more than 1,500 cases of malaria, and currently there is limited access to an intravenously administered (IV) drug needed for the more serious cases.

Monkey malaria breakthrough offers cure for relapsing malaria
A breakthrough in monkey malaria research by two University of Otago scientists could help scientists diagnose and treat a relapsing form of human malaria.

Getting to zero malaria cases in zanzibar
New research led by the Johns Hopkins Center for Communication Programs, Ifakara Health Institute and the Zanzibar Malaria Elimination Program suggests that a better understanding of human behavior at night -- when malaria mosquitoes are biting -- could be key to preventing lingering cases.

Widely used malaria treatment to prevent malaria in pregnant women
A global team of researchers, led by a research team at the Liverpool School of Tropical Medicine (LSTM), are calling for a review of drug-based strategies used to prevent malaria infections in pregnant women, in areas where there is widespread resistance to existing antimalarial medicines.

Protection against Malaria: A matter of balance
A balanced production of pro and anti-inflammatory cytokines at two years of age protects against clinical malaria in early childhood, according to a study led by ISGlobal, an institution supported by ''la Caixa'' Foundation.

The math of malaria
A new mathematical model for malaria shows how competition between parasite strains within a human host reduces the odds of drug resistance developing in a high-transmission setting.

Read More: Malaria News and Malaria Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.